Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach...Show More

Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach of 15 million patients by the time of the report. Lilly engaged with investors on topics such as drug pricing, global product access, and enterprise risks. The board proposed management initiatives for the 2024 annual meeting to eliminate the classified board structure and supermajority voting requirements in the articles of incorporation. The company's commitment to making life better for people worldwide was reiterated, with the Annual Meeting set to welcome shareholders virtually on May 6, 2024.